{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:52:41Z","timestamp":1760043161496},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/adm.0b013e31827f9bdf","type":"journal-article","created":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T15:15:11Z","timestamp":1360163711000},"page":"102-107","source":"Crossref","is-referenced-by-count":7,"title":["Association Between Risk Behaviors and Antiretroviral Resistance in HIV-Infected Patients Receiving Opioid Agonist Treatment"],"prefix":"10.1097","volume":"7","author":[{"given":"Jeanette M.","family":"Tetrault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Kozal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Chiarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn E.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An T.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"1","key":"R2-3-20210126","first-page":"44","article-title":"Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients.","volume":"41","author":"Fisher","year":"2006","journal-title":"JAIDS"},{"key":"R3-3-20210126","first-page":"CD004145","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection. Meta-Analysis Review.","volume":"8","author":"Gowing","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"R6-3-20210126","first-page":"106","article-title":"HIV drug resistance and HIV transmission risk behaviors among active injection drug users.","volume":"40","author":"Kozal","year":"2005","journal-title":"JAIDS"},{"issue":"2","key":"R7-3-20210126","first-page":"72","article-title":"A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care.","volume":"8","author":"Kozal","year":"2006","journal-title":"MedGenMed"},{"issue":"16","key":"R8-3-20210126","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/00002030-200411050-00011","article-title":"Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care.","volume":"18","author":"Kozal","year":"2004","journal-title":"AIDS"},{"issue":"6","key":"R9-3-20210126","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3851\/IMP1851","article-title":"Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R among different HIV subtypes and the effects of antiretroviral drug exposure on variant levels.","volume":"16","author":"Kozal","year":"2011","journal-title":"Antivir Ther"},{"issue":"6","key":"R10-3-20210126","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1310\/hct0806-357","article-title":"for Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies.","volume":"8","author":"Kozal","year":"2007","journal-title":"HIV Clin Trials"},{"issue":"7","key":"R11-3-20210126","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nm0796-753","article-title":"Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.","volume":"2","author":"Kozal","year":"1996","journal-title":"Nat Med"},{"issue":"6","key":"R12-3-20210126","doi-asserted-by":"crossref","first-page":"e10952","DOI":"10.1371\/journal.pone.0010952","article-title":"Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.","volume":"5","author":"Lataillade","year":"2010","journal-title":"PLoS ONE"},{"issue":"6","key":"R13-3-20210126","doi-asserted-by":"crossref","first-page":"e6079","DOI":"10.1371\/journal.pone.0006079","article-title":"Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.","volume":"4","author":"Le","year":"2009","journal-title":"PLoS ONE"},{"issue":"13","key":"R14-3-20210126","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis.","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"R15-3-20210126","first-page":"555","article-title":"Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: Results from a randomized controlled trial.","volume":"46","author":"Maru","year":"2007","journal-title":"JAIDS"},{"issue":"1","key":"R16-3-20210126","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients: The addiction severity index.","volume":"168","author":"McLellan","year":"1980","journal-title":"J Nerv Ment Dis"},{"issue":"9","key":"R17-3-20210126","first-page":"1049","article-title":"Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up.","volume":"6","author":"Metzger","year":"1993","journal-title":"JAIDS"},{"issue":"2","key":"R19-3-20210126","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00002030-200001280-00010","article-title":"Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment: The Manif 2000 study group.","volume":"14","author":"Moatti","year":"2000","journal-title":"AIDS"},{"issue":"3","key":"R20-3-20210126","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1086\/427212","article-title":"Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy.","volume":"40","author":"Novak","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"R22-3-20210126","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1086\/600073","article-title":"Predictive value of HIV-1 genotypic resistance test interpretation algorithms.","volume":"200","author":"Rhee","year":"2009","journal-title":"J Infect Dis"},{"issue":"5","key":"R23-3-20210126","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"for Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.","volume":"199","author":"Simen","year":"2009","journal-title":"J Infect Dis"},{"issue":"2","key":"R27-3-20210126","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1360-0443.2004.00963.x","article-title":"Decreasing international HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users.","volume":"100","author":"Sullivan","year":"2005","journal-title":"Addiction"},{"issue":"1","key":"R29-3-20210126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1521-0391.2009.00003.x","article-title":"The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphinenaloxone for the treatment of opioid dependence.","volume":"19","author":"Sullivan","year":"2010","journal-title":"Am J Addict"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0b013e31827f9bdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:08:15Z","timestamp":1620943695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01271255-201303000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0b013e31827f9bdf","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}